Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Investor presentation posted April 7, 2026 for use in meetings with investors.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Investor presentation posted April 7, 2026 for use in meetings with investors
- Exhibit 99.1 contains the company’s corporate presentation and may provide updated strategy or pipeline context
Item EX-99.1 · Exhibit EX-99.1
- Positive Phase 3 SELVA results: mean mLM-IGA improvement +2.13, all primary and secondary endpoints p<0.001
- 95% of evaluable participants improved; 86% were “Much Improved” or “Very Much Improved”
- NDA submission targeted for 2H 2026, with FDA pre-NDA meeting expected Q2 2026
- Potential first FDA-approved therapy for >30,000 diagnosed U.S. microcystic LM patients
- Pipeline expansion: cVM Phase 3 expected 2H 2026; angiokeratoma Phase 2 expected Q2 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.